On October 24, 2024, Dyno Therapeutics, a gene technology company that utilizes artificial intelligence for in vivo gene delivery, announced its second research collaboration with Roche to jointly develop the next generation of adeno-associated virus (AAV) vectors for gene therapy targeting neurological diseases.Dyno and Roche previously announced a research collaboration and licensing agreement in October 2020 for neurological disorders and liver targeted therapies. According to this new collaboration agreement, Dyno Therapeutics will provide Roche with more opportunities to utilize the company's leading platform and sequence design technology in the field to achieve in vivo gene delivery.

The existing gene therapies mainly use a small amount of naturally occurring AAV vectors, which have problems such as low delivery efficiency, pre-existing immunity, and manufacturability. To overcome these challenges, Dyno took the lead in applying artificial intelligence and high-throughput in vivo data acquisition technology to engineer the AAV virus capsid, in order to improve tissue targeting, immune evasion, and manufacturability. The combination of Dyno's low injection efficiency acceleration performance (LEAPSM) technology and the ability to perform billions of in vivo sequence functional measurements per month can accelerate the optimization of the capsid, leading to successful treatment. As a platform established to address the most critical challenges faced by gene therapy developers, Dyno's industry-leading gene delivery solutions enable Dyno partners to develop better gene therapies.

According to the terms of the new agreement, Dyno is responsible for designing and discovering novel AAV capsids with better functional characteristics. Roche is responsible for conducting capsid validation studies on various candidate products for neural system gene therapy using the new Dyno capsid, and further conducting preclinical, clinical, and commercial activities. Roche will make a $50 million advance payment to Dyno and make additional payments during the collaborative research phase. In addition, Roche may also pay a total of over $1 billion in preclinical, clinical, and sales milestone payments, as well as royalties on net sales of commercial products.

Dr. Eric Kelsic, founder and CEO of Dyno, said, "This new collaboration with Roche is dedicated to developing the next generation of gene therapies to treat underserved patients with life changing neurological disorders. This demonstrates the outstanding progress made by the Dyno platform and our commitment to partners in all projects. Our approach combines extensive in vivo data with the world's most advanced sequence function prediction artificial intelligence models, giving Dyno's capsid engineers industry-leading capabilities to solve the long-standing challenge of therapeutic gene delivery. Dyno's platform brings the entire field closer to achieving a future where all gene therapies are safe and effective. And it can be widely provided to all patients in needBoris L. Za ï tra, Head of Business Development at Roche, said, "We are delighted to take our collaboration with Dyno Therapeutics to new heights. The combination of our knowledge and resources will enable us to explore new therapies for traditionally difficult to treat neurological disorders. We are committed to making significant progress in this field, and partnering with companies like Dyno Therapeutics is part of it. Our previous collaboration with Dyno Therapeutics gives us great confidence to increase our investment in therapeutic gene delivery and support our neurological disease product portfolio.

About Dyno Therapeutics

Dyno Therapeutics is building high-performance gene technology to change the treatment outcomes for patients by overcoming the challenges of in vivo gene delivery faced by therapy developers. Dyno's platform combines artificial intelligence with high-throughput experiments, accelerating the design speed of AAV capsids and greatly outperforming existing gene delivery vectors. Just as the exponential breakthrough in computer chip technology has driven the artificial intelligence revolution, Dyno's multifunctional platform is also utilizing fundamental advances in in in vivo multiplexing technology and high-performance computing to address various therapeutic challenges. Dyno drives therapeutic innovation by collaborating with leading gene therapy developers, including Astellas, Roche, and Sarepta, as well as technology companies such as Nvidia. For more information, please visit:
www.dynotx.com

Dyno's collaborations with other pharmaceutical companies can be found at:
AI+Gene Therapy | Dyno and Astellas announce collaboration with a total potential value exceeding $1.6 billion